Pseudomonas aeruginosa population structure revisited.

PloS One
Jean-Paul PirnayDaniel De Vos

Abstract

At present there are strong indications that Pseudomonas aeruginosa exhibits an epidemic population structure; clinical isolates are indistinguishable from environmental isolates, and they do not exhibit a specific (disease) habitat selection. However, some important issues, such as the worldwide emergence of highly transmissible P. aeruginosa clones among cystic fibrosis (CF) patients and the spread and persistence of multidrug resistant (MDR) strains in hospital wards with high antibiotic pressure, remain contentious. To further investigate the population structure of P. aeruginosa, eight parameters were analyzed and combined for 328 unrelated isolates, collected over the last 125 years from 69 localities in 30 countries on five continents, from diverse clinical (human and animal) and environmental habitats. The analysed parameters were: i) O serotype, ii) Fluorescent Amplified-Fragment Length Polymorphism (FALFP) pattern, nucleotide sequences of outer membrane protein genes, iii) oprI, iv) oprL, v) oprD, vi) pyoverdine receptor gene profile (fpvA type and fpvB prevalence), and prevalence of vii) exoenzyme genes exoS and exoU and viii) group I pilin glycosyltransferase gene tfpO. These traits were combined and analysed using ...Continue Reading

References

Jun 1, 1975·Journal of Clinical Microbiology·C H Zierdt, R L Williams
Jan 1, 1991·The Journal of Antimicrobial Chemotherapy·J M Hamilton-Miller
Mar 1, 1986·Journal of Medical Microbiology·T L PittE M Cooke
Jun 1, 1987·European Journal of Clinical Microbiology·N J LegakisJ Papavassiliou
Apr 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D AllemeerschH Van Poppel
Jul 1, 1983·Journal of Bacteriology·J Kuzio, A M Kropinski
Nov 1, 1983·Journal of Medical Microbiology·A R PenkethJ C Batten
Aug 1, 1982·Journal of Clinical Microbiology·J J FarmerC D Brokopp
Nov 11, 1995·Nucleic Acids Research·P VosM Kuiper
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F GrattardA D Mbida
Apr 14, 1995·The Journal of Biological Chemistry·C DuportY Michel-Briand
Jun 1, 1994·Applied and Environmental Microbiology·U RömlingB Tümmler
Mar 1, 1994·Journal of Clinical Microbiology·A ElaichouniM Vaneechoutte
Jun 1, 1993·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·I KobayashiS Goto
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J M SmithB G Spratt
Mar 1, 1996·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·A Van Belkum
Jan 1, 1997·Microbiology·Jean-Marie MeyerHerbert Budzikiewicz

❮ Previous
Next ❯

Citations

Jul 23, 2013·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·YanQing TongChuFeng Wang
Nov 20, 2013·Proceedings of the National Academy of Sciences of the United States of America·David SkurnikGerald B Pier
Dec 12, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P Basset, D S Blanc
Apr 22, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Satoshi YamaguchiYuichi Ohashi
Apr 30, 2014·BMC Genomics·María-Victoria Grosso-BecerraGloria Soberón-Chávez
Dec 11, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jeremy R DettmanRees Kassen
Dec 2, 2010·Microbiology and Molecular Biology Reviews : MMBR·Vanderlene L KungAlan R Hauser
Jun 23, 2012·American Journal of Respiratory and Critical Care Medicine·Weihui WuGregory P Priebe
Mar 1, 2014·Expert Review of Vaccines·Gregory P Priebe, Joanna B Goldberg
Oct 1, 2015·Environmental Microbiology Reports·Lutz WiehlmannBurkhard Tümmler
Jul 6, 2011·Research in Microbiology·Amélie DeredjianSylvie Nazaret
May 23, 2013·The New Phytologist·Caroline L MonteilBoris A Vinatzer
Aug 14, 2012·Environmental Microbiology·Dmitri V MavrodiLinda S Thomashow
Jun 25, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Pholawat TingpejColin Harbour
Nov 12, 2013·MicrobiologyOpen·Anthony De SoyzaCraig Winstanley
Mar 8, 2016·Expert Review of Respiratory Medicine·K A RamsayT J Kidd
Jan 16, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A A WitneyJ Hinds
Oct 21, 2015·Frontiers in Microbiology·Luca FreschiRoger C Levesque
Oct 7, 2015·Frontiers in Microbiology·Marta Michalska, Philipp Wolf
Apr 6, 2013·Journal of Medical Microbiology·Kate MartinJane F Turton
Sep 17, 2014·MicrobiologyOpen·Maarten G K GhequireRené De Mot
Aug 27, 2014·Environmental Microbiology·Rolf HilkerBurkhard Tümmler
Aug 26, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Antonio OliverCarlos Juan
Sep 28, 2010·Water Research·Tamara Garcia-ArmisenPierre Cornelis
Jan 8, 2015·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Marina Bubonja-SonjeMaja Abram
Dec 7, 2014·Genome Biology and Evolution·Jeremy R DettmanRees Kassen
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Michel Tibayrenc, Francisco J Ayala
Jun 3, 2017·Annals of the New York Academy of Sciences·Julie JeukensRoger C Levesque

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
PCR
total collection
electrophoresis

Software Mentioned

GeneScan
MST
FAFLP
VITEK
BioNumerics

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.